ReviewBiochemical Society transactions2026
Propionic acidemia as a framework for understanding the impact of disturbed propionyl-CoA on histone modifications.
Review in Biochemical Society transactions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Histone propionylation-the transfer of a three-carbon propionyl group from propionyl-CoA to lysine residues-is an emerging post-translational modification (PTM) with potential effects on gene expression. Interest in this PTM has grown because propionyl-CoA is at the interface between valine, isoleucine, methionine, and threonine catabolism, odd-chain fatty acid oxidation, gut-derived propionate assimilation, and anaplerotic entry into the tricarboxylic acid cycle. An informative context for studying the influence of disturbed propionyl-CoA metabolism on chromatin state and phenotype is propionic acidemia (PA), where loss-of-function mutations in genes coding propionyl-CoA carboxylase (PCC) lead to the accumulation of propiogenic substrates and propionyl-CoA. At least some of the clinical manifestations of PA (cardiomyopathy, arrhythmia, and neurological injury) may relate to altered histone propionylation, and a challenge is to distinguish these responses from metabolic toxicity. To that end, mouse models of PA are promising tools for connecting molecular-level histone changes to systems-level phenotypes. In this review, we describe recent advances in propionyl-CoA biology in the context of histone modifications and gene regulation. We present milestone studies that identified histone PTMs and described their association with phenotype. We also highlight emerging questions related to propionyl-CoA handling, its compartmentalization, and tissue specificity of actions, and discuss the relative contribution of histone propionylation versus other forms of acylation and broader metabolic stress. On balance, the literature supports a model in which propionyl-CoA exerts regulatory actions on chromatin state, but how this might be targeted therapeutically in PA and the implications for other metabolic disturbances remain important areas for further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.